What is the price target for PRAX stock?
22 analysts have analysed PRAX and the average price target is 612.72 USD. This implies a price increase of 99.78% is expected in the next year compared to the current price of 306.69.
PRAXIS PRECISION MEDICINES I (PRAX) Forecast, Price Target & Analyst Ratings
NASDAQ:PRAX • US74006W2070
Current stock price
306.69 USD
-3.42 (-1.1%)
At close:
306.69 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PRAXIS PRECISION MEDICINES I (PRAX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Apr 30, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$3.62
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$612.72
Upside
+ 99.78%
From current price of $306.69 to mean target of $612.72, Based on 22 analyst forecasts
Low
$131.30
Median
$535.50
High
$1,307.25
Price Target Revisions
1 Month
-1.04%
3 Months
49.26%
Price Target Summary
22 Wall Street analysts provided a forecast for the next 12 months for PRAX. The average price target is 612.72 USD. This implies a price increase of 99.78% is expected in the next year compared to the current price of 306.69.
The average price target has been revised upward by 49.26% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.73%
PRAX was analyzed by 22 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about PRAX.
In the previous month the buy percentage consensus was at a similar level.
PRAX was analyzed by 22 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-04-06 | BTIG | Reiterate | Buy -> Buy |
| 2026-02-24 | Wolfe Research | Initiate | Outperform |
| 2026-02-20 | Wedbush | Maintains | Underperform -> Underperform |
| 2026-02-20 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-20 | Truist Securities | Maintains | Buy -> Buy |
| 2026-02-20 | Baird | Maintains | Outperform -> Outperform |
| 2026-02-10 | Guggenheim | Maintains | Buy -> Buy |
| 2026-02-04 | Needham | Maintains | Buy -> Buy |
| 2026-02-02 | Wells Fargo | Initiate | Equal-Weight |
| 2026-01-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-28 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-01-12 | Wedbush | Maintains | Underperform -> Underperform |
| 2025-12-29 | BTIG | Maintains | Buy -> Buy |
| 2025-12-15 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-12-09 | Guggenheim | Maintains | Buy -> Buy |
| 2025-12-09 | Jefferies | Maintains | Buy -> Buy |
| 2025-12-08 | TD Cowen | Maintains | Buy -> Buy |
| 2025-12-08 | BTIG | Maintains | Buy -> Buy |
| 2025-12-08 | Needham | Maintains | Buy -> Buy |
| 2025-12-08 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-12-05 | Needham | Maintains | Buy -> Buy |
| 2025-12-05 | Wedbush | Maintains | Underperform -> Underperform |
| 2025-12-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 30, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$3.62
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- -10.04%
- Number of Analysts
- 17
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
1.43%
EPS (3 Months)
-7.37%
Next Earnings Summary
PRAX is expected to report earnings on 4/30/2026. The consensus EPS estimate for the next earnings is -3.62 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.447M | 8.553M 249.53% | 40.8K -100.00% | 4.614M | 299.72M 6,395.88% | 1.076B 259.00% | 2.234B 107.62% | 3.528B 57.92% | 6.033B 71.00% | 7.918B 31.24% | 9.187B 16.03% | ||
| EBITDA YoY % growth | -213.57M -27.77% | -125.941M 41.03% | -199.807M -58.65% | -303.701M -63.19% | -442.322M -35.66% | -381.78M 13.69% | -109.468M 71.33% | 238.39M 317.77% | 826.12M 246.54% | 548M -33.67% | 908.62M 65.81% | 1.266B 39.33% | |
| EBIT YoY % growth | -213.99M -27.89% | -126.373M 40.94% | -200.165M -58.39% | -313.858M -62.96% | -445.919M -36.70% | -340.365M 23.67% | 257.16M 175.55% | 1.275B 395.80% | 2.31B 81.18% | 3.904B 69.00% | 4.919B 26.00% | 5.638B 14.62% | |
| Operating Margin | N/A | -5,164.41% | -2,340.29% | -769,260.50% | -9,664.47% | -113.56% | 23.90% | 57.07% | 65.48% | 64.71% | 62.12% | 61.37% | |
| EPS YoY % growth | -69.90 -19.79% | -23.67 66.14% | -10.27 56.61% | -13.31 -31.06% | -15.37 -14.22% | -11.18 27.28% | 4.87 143.52% | 41.81 759.27% | 70.49 68.59% | 107.36 52.31% | 125.11 16.53% | 138.58 10.77% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -3.62 -10.04% | -3.74 -12.89% | -3.91 -16.50% | -3.91 -11.62% | -4.12 -13.73% | -3.73 0.10% | -2.96 24.43% | -1.47 62.40% |
| Revenue Q2Q % growth | 632.533K | 5.382M | 10.51M | 29.715M | 60.751M 9,504.41% | 108.87M 1,922.85% | ||
| EBITDA Q2Q % growth | -105.111M -40.75% | -107.253M -41.17% | -112.737M -44.08% | -117.221M -20.97% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -102.642M -37.35% | -106.559M -40.09% | -112.677M -43.80% | -115.165M -18.67% | -131.743M -28.35% | -124.882M -17.20% | -104.897M 6.91% | -66.769M 42.02% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
33.17%
EPS Next 5 Year
48.56%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
2,876.58%
Revenue Next 5 Year
871.35%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
18.20%
EBIT Next 5 Year
35.88%
PRAXIS PRECISION MEDICINES I / PRAX Forecast FAQ
When does PRAXIS PRECISION MEDICINES I (PRAX) report earnings?
PRAXIS PRECISION MEDICINES I (PRAX) will report earnings on 2026-04-30.
What are the consensus estimates for PRAXIS PRECISION MEDICINES I (PRAX) next earnings?
The consensus EPS estimate for the next earnings of PRAXIS PRECISION MEDICINES I (PRAX) is -3.62 USD and the consensus revenue estimate is 0 USD.
How do analysts rate PRAXIS PRECISION MEDICINES I (PRAX)?
The consensus rating for PRAXIS PRECISION MEDICINES I (PRAX) is 82.7273 / 100 . This indicates that analysts generally have a positive outlook on the stock.